Table 5. Relationship between the expression of AKR1C1 in HCC tissues and the clinical characteristics of HCC patients.
| Parameters | High-expression group (n=56) | Low-expression group (n=34) | P |
|---|---|---|---|
| Age (years) | 0.3615 | ||
| ≤60 (n=29) | 16 | 13 | |
| >60 (n=61) | 40 | 21 | |
| Gender | 0.8068 | ||
| Male (n=67) | 41 | 26 | |
| Female (n=23) | 15 | 8 | |
| AFP (μg/L) | >0.9999 | ||
| ≤20 (n=31) | 19 | 12 | |
| >20 (n=59) | 37 | 22 | |
| Cirrhosis | 0.0011** | ||
| Negative (n=22) | 7 | 15 | |
| Positive (n=68) | 49 | 19 | |
| Tumor number | 0.0101* | ||
| ≤1 (n=62) | 33 | 29 | |
| >1 (n=28) | 23 | 5 | |
| Lymph gland metastasis | 0.0032** | ||
| Negative (n=56) | 28 | 28 | |
| Positive (n=34) | 28 | 6 | |
| TNM stage | 0.0204* | ||
| I/II (n=60) | 32 | 28 | |
| III (n=30) | 24 | 6 | |
*P<0.05, **P<0.01. HCC, hepatocellular carcinoma; TNM, tumour-node-metastasis; AFP, alpha-fetoprotein.